UBS Downgrades Legend Biotech to Neutral, Lowers Price Target to $28

Benzinga Newsdesk www.benzinga.com Negative 86.3%

Neg 86.3% Neu 0% Pos 0%

UBS analyst Ashwani Verma downgrades Legend Biotech (NASDAQ:LEGN) from Buy to Neutral and lowers the price target from $49 to $28.